Specialists at the Rambam Health Care Campus in Haifa have successfully used experimental noninvasive brain technology to treat a patient suffering from extreme opioid dependence. The procedure, which targeted the brain’s reward system, helped the patient cease using roughly 130 pills daily after a single 20-minute session, according to reports from The Jerusalem Post and Ynetnews.
Targeting the Brain’s Reward Circuit
The patient, a man in his 40s from northern Israel identified as H., developed an addiction to painkillers following a neck injury several years ago. While his physical pain eventually subsided, his chemical dependence escalated, reaching a peak of approximately 130 pills per day. Doctors at Rambam’s Pain Medicine Institute described his condition not as a response to lingering pain, but as a physiological necessity to maintain functioning.
To address this, medical teams intervened in the nucleus accumbens, a brain region central to pleasure, satisfaction, and reward. By using focused sound waves—a technology developed by the Israeli company Insightec—clinicians performed neuromodulation without the need for invasive surgery or thermal damage to brain tissue. This approach is similar to methods currently used to treat essential tremor and Parkinson’s-related tremors, though it is now being applied to neural pathways associated with addiction. The procedure utilizes Magnetic Resonance Imaging (MRI) guidance to pinpoint the exact coordinates within the brain, allowing for high-precision energy delivery that disrupts the neural loops reinforced by chronic substance use.
Clinical Outcomes and Unexpected Side Effects
The results of the 20-minute procedure were immediate, according to Dr. Lior Lev-Tov, director of the functional neurosurgery unit at Rambam. During the treatment, the medical team observed a rapid decline in the patient’s craving for opioids. Follow-up tests conducted one week later confirmed the patient was negative for opioids and other substances.
“The patient reported a craving level of zero out of 10 for using the drug, and even an unexpected side effect, a drastic decline in his desire for cigarettes.”
Dr. Lior Lev-Tov, Rambam Health Care Campus, via Ynetnews
Beyond the cessation of opioid use, H. reported a significant reduction in nicotine dependency, dropping from three packs of cigarettes a day to only a few. He also reported no further urge to consume alcohol. Dr. Amir Minerbi, director of the Pain Medicine Institute, characterized the outcome as a significant shift in how the patient manages his health.
“H. was no longer suffering from pain. He simply needed that substance in his blood so he would be calm and able to function.”
Dr. Amir Minerbi, Rambam Health Care Campus, via The Jerusalem Post
Context and Regulatory Framework
Neuromodulation for psychiatric and addictive disorders remains a rigorous area of clinical investigation. In standard clinical practice, addiction is often treated through a combination of behavioral therapy and medication-assisted treatment (MAT), such as buprenorphine or methadone. Experimental interventions like the one performed at Rambam represent a shift toward addressing the neurobiological underpinnings of addiction—the physical changes in brain circuitry that make withdrawal and relapse difficult for patients to overcome.
The technology utilized, focused ultrasound, is regulated under strict clinical trial protocols. Because the brain is highly sensitive, any intervention targeting the nucleus accumbens must be vetted through institutional review boards and, in many jurisdictions, national health ministries to ensure patient safety. The use of this technology for addiction is still considered investigational, meaning it is not yet a standard-of-care procedure available in general clinical settings.
Broader Implications for Global Opioid Treatment
The procedure at Rambam is part of an ongoing international study involving a limited number of medical centers in the United States and Israel. While opioid painkillers remain a vital tool for managing short-term pain, their potential for addiction presents a persistent medical challenge. The opioid crisis has claimed hundreds of thousands of lives in the United States, with annual economic damages estimated at $60 billion.
Experts involved in the study suggest this platform could eventually redefine treatment protocols for various conditions by offering noninvasive access to deep, sensitive brain regions. Dr. Lev-Tov noted that the technology allows for targeted influence over brain activity depending on the specific disease being treated. As the international study continues, the medical community will monitor whether these results can be replicated across a broader patient population. For individuals struggling with substance dependence, these initial findings offer a potential new avenue for intervention. However, it is essential to emphasize that this is an experimental procedure. Anyone struggling with substance use disorder should consult with their primary care physician or a qualified addiction specialist to discuss established, evidence-based treatment options currently available.
